New hope for tough prostate cancers: first human trial launches
NCT ID NCT05997615
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 28 times
Summary
This early-stage study tests a new drug, VIR-5500, in people with advanced prostate cancer that no longer responds to hormone therapy. The trial will first find a safe dose, then test it alone or with other drugs. About 390 participants will join to see if the drug is safe and shows signs of shrinking tumors or lowering PSA levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE-REFRACTORY PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigational Site Number: 100
RECRUITINGMelbourne, 3000, Australia
-
Investigational Site Number: 101
RECRUITINGSydney, 2010, Australia
-
Investigational Site Number: 250
RECRUITINGBarcelona, 08035, Spain
-
Investigational Site Number: 251
WITHDRAWNBarcelona, 08023, Spain
-
Investigational Site Number: 252
RECRUITINGMadrid, 28223, Spain
-
Investigational Site Number: 253
RECRUITINGPamplona, 31008, Spain
-
Investigational Site Number: 254
RECRUITINGMadrid, 28027, Spain
-
Investigational Site Number: 300
RECRUITINGLondon, SM2 5PT, United Kingdom
-
Investigational Site Number: 400
RECRUITINGSeattle, Washington, 98109, United States
-
Investigational Site Number: 401
RECRUITINGHouston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.